EP-282 is under clinical development by EPICS Therapeutics and currently in Phase I for Inflammation. According to GlobalData, Phase I drugs for Inflammation have a 46% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how EP-282’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

EP-282 overview

EP-282 is under development for the treatment of intestinal infection, unspecified cancer, and inflammation. The drug candidates acts by targeting FFAR2.

EPICS Therapeutics overview

EPICS Therapeutics is a biotechnology company focused on discovery and development of first-in-class treatments acting on RNA epigenetic mechanisms. The company is developing novel small molecules anti-cancer drugs based on RNA modification pathways in oncology and other diseases. EPICS Therapeutics also offers an integrated services solution for G Protein-Coupled Receptors (GPCRs) R&D projects. The company seeks to work in partnership with other biotechnology and drug development companies to advance its technology expertise and pipeline products. The company is spin off from University of Brussels (ULB). EPICS Therapeutics is headquartered in Gosselies, Belgium.

For a complete picture of EP-282’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.